MYSC Trademark

Trademark Overview

On Friday, October 18, 2019, a trademark application was filed for MYSC with the United States Patent and Trademark Office. The USPTO has given the MYSC trademark a serial number of 88660271. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 15, 2024. This trademark is owned by Bristol-Myers Squibb Company. The MYSC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical p...
mysc

General Information

Serial Number88660271
Word MarkMYSC
Filing DateFriday, October 18, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 13, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 23, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Tuesday, October 22, 2019NEW APPLICATION ENTERED
Wednesday, October 23, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 24, 2020ASSIGNED TO EXAMINER
Wednesday, January 29, 2020NON-FINAL ACTION WRITTEN
Wednesday, January 29, 2020NON-FINAL ACTION E-MAILED
Wednesday, January 29, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, July 26, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, July 26, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 27, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 17, 2020FINAL REFUSAL WRITTEN
Monday, August 17, 2020FINAL REFUSAL E-MAILED
Wednesday, February 17, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, August 17, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, February 17, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 18, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 9, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 13, 2021PUBLISHED FOR OPPOSITION
Tuesday, April 13, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 8, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 8, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, December 8, 2021SOU EXTENSION 1 FILED
Wednesday, December 8, 2021SOU EXTENSION 1 GRANTED
Friday, December 10, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 26, 2022SOU TEAS EXTENSION RECEIVED
Thursday, May 26, 2022SOU EXTENSION 2 FILED
Thursday, May 26, 2022SOU EXTENSION 2 GRANTED
Saturday, May 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 5, 2022SOU TEAS EXTENSION RECEIVED
Monday, December 5, 2022SOU EXTENSION 3 FILED
Monday, December 5, 2022SOU EXTENSION 3 GRANTED
Wednesday, December 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 30, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 30, 2023SOU EXTENSION 4 FILED
Tuesday, May 30, 2023SOU EXTENSION 4 GRANTED
Thursday, June 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, November 27, 2023SOU TEAS EXTENSION RECEIVED
Thursday, December 7, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, November 27, 2023SOU EXTENSION 5 FILED
Friday, December 8, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 15, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, July 15, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Thursday, December 7, 2023SOU EXTENSION 5 GRANTED

Related Keywords

mysc diseases pharmaceutical human preparations anti cancer immune disorders system treatment